JP2023502030A5 - - Google Patents

Info

Publication number
JP2023502030A5
JP2023502030A5 JP2022527713A JP2022527713A JP2023502030A5 JP 2023502030 A5 JP2023502030 A5 JP 2023502030A5 JP 2022527713 A JP2022527713 A JP 2022527713A JP 2022527713 A JP2022527713 A JP 2022527713A JP 2023502030 A5 JP2023502030 A5 JP 2023502030A5
Authority
JP
Japan
Prior art keywords
peaks
methyl
compound
crystalline
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022527713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502030A (ja
JP7726879B2 (ja
Filing date
Publication date
Priority claimed from JP2019206311A external-priority patent/JP2021080177A/ja
Application filed filed Critical
Publication of JP2023502030A publication Critical patent/JP2023502030A/ja
Publication of JP2023502030A5 publication Critical patent/JP2023502030A5/ja
Priority to JP2025132388A priority Critical patent/JP2025159062A/ja
Application granted granted Critical
Publication of JP7726879B2 publication Critical patent/JP7726879B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022527713A 2019-11-14 2020-11-12 複素環式化合物およびその使用 Active JP7726879B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025132388A JP2025159062A (ja) 2019-11-14 2025-08-07 複素環式化合物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019206311A JP2021080177A (ja) 2019-11-14 2019-11-14 複素環化合物及びその用途
JP2019206311 2019-11-14
PCT/IB2020/000962 WO2021094832A1 (en) 2019-11-14 2020-11-12 Heterocyclic nmda antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025132388A Division JP2025159062A (ja) 2019-11-14 2025-08-07 複素環式化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2023502030A JP2023502030A (ja) 2023-01-20
JP2023502030A5 true JP2023502030A5 (cg-RX-API-DMAC10.html) 2023-11-20
JP7726879B2 JP7726879B2 (ja) 2025-08-20

Family

ID=74141594

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019206311A Pending JP2021080177A (ja) 2019-11-14 2019-11-14 複素環化合物及びその用途
JP2022527713A Active JP7726879B2 (ja) 2019-11-14 2020-11-12 複素環式化合物およびその使用
JP2025132388A Pending JP2025159062A (ja) 2019-11-14 2025-08-07 複素環式化合物およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019206311A Pending JP2021080177A (ja) 2019-11-14 2019-11-14 複素環化合物及びその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025132388A Pending JP2025159062A (ja) 2019-11-14 2025-08-07 複素環式化合物およびその使用

Country Status (21)

Country Link
US (3) US12630509B2 (cg-RX-API-DMAC10.html)
EP (1) EP4058430A1 (cg-RX-API-DMAC10.html)
JP (3) JP2021080177A (cg-RX-API-DMAC10.html)
KR (1) KR20220102629A (cg-RX-API-DMAC10.html)
CN (1) CN114728900A (cg-RX-API-DMAC10.html)
AR (1) AR120452A1 (cg-RX-API-DMAC10.html)
AU (1) AU2020385250B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022008367A2 (cg-RX-API-DMAC10.html)
CA (1) CA3158352A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022001241A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022008012A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220275A (cg-RX-API-DMAC10.html)
DO (1) DOP2022000099A (cg-RX-API-DMAC10.html)
EC (1) ECSP22037602A (cg-RX-API-DMAC10.html)
IL (1) IL292639A (cg-RX-API-DMAC10.html)
JO (1) JOP20220108A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022005778A (cg-RX-API-DMAC10.html)
PE (1) PE20221767A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022551173A1 (cg-RX-API-DMAC10.html)
TW (1) TWI908745B (cg-RX-API-DMAC10.html)
WO (1) WO2021094832A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
TWI873185B (zh) 2019-09-16 2025-02-21 日商武田藥品工業股份有限公司 唑稠合之嗒-3(2h)-酮衍生物
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) * 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
WO2026060343A1 (en) 2024-09-16 2026-03-19 Neurocrine Biosciences, Inc. Solid forms comprising a nr2b nam antagonist

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492382A1 (fr) 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US5252563A (en) 1991-12-19 1993-10-12 G. D. Searle & Company 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrimidine compounds for treatment of neurotoxic injury
CA2191979A1 (en) 1994-06-20 1995-12-28 Muneo Takatani Condensed imidazole compounds, their production and use
JPH08319288A (ja) 1994-06-20 1996-12-03 Takeda Chem Ind Ltd 縮合イミダゾール誘導体、その製造法及び剤
JP3439551B2 (ja) 1994-11-08 2003-08-25 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US6387938B1 (en) 1996-07-05 2002-05-14 Mochida Pharmaceutical Co., Ltd. Benzimidazole derivatives
KR20000022398A (ko) 1996-07-05 2000-04-25 모치다 에이 신규 벤조이미다졸 유도체
EP1586584A1 (en) 1996-08-27 2005-10-19 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids
JP2000159747A (ja) 1998-09-21 2000-06-13 Takeda Chem Ind Ltd 新規チオ―ル誘導体、その製造法および用途
US6420415B1 (en) 1998-09-21 2002-07-16 Takeda Chemical Industries, Ltd. Thiol compounds, their production and use
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
EP1194449B1 (en) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
AU1153601A (en) 1999-10-29 2001-05-08 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole NMDA NR2B antagonists
US20020151534A1 (en) 2001-02-02 2002-10-17 Ries Uwe Joerg Antithrombotic compounds
DE10111842A1 (de) 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Antithrombotische Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
EP1390034A4 (en) 2001-04-03 2005-07-13 Merck & Co Inc N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS
JPWO2003035641A1 (ja) 2001-10-22 2005-02-10 塩野義製薬株式会社 新規カルバモイルピロリドン誘導体
JP2004002405A (ja) 2002-04-26 2004-01-08 Takeda Chem Ind Ltd 新規チオール誘導体、その製造法および用途
CA2483515A1 (en) * 2002-04-26 2003-11-06 Takeda Pharmaceutical Company Limited Novel thiol derivative, method for producing the same and use thereof
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
JP2004161716A (ja) 2002-11-15 2004-06-10 Takeda Chem Ind Ltd Jnk阻害剤
CA2521907A1 (en) 2003-04-10 2004-10-21 Pfizer Inc. Bicyclic compounds as nr2b receptor antagonists
US20050137187A1 (en) 2003-12-23 2005-06-23 Souers Andrew J. Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
HUP0401523A3 (en) 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
JP5031745B2 (ja) 2005-08-12 2012-09-26 アストラゼネカ アクチボラグ 代謝型グルタミン酸受容体増強性イソインドロン
US20080234318A1 (en) 2005-08-31 2008-09-25 Kristjan Gudmundsson Chemical Compounds
AR057218A1 (es) 2005-12-15 2007-11-21 Astra Ab Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法
WO2007098352A2 (en) 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
WO2009004430A1 (en) * 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
AU2010210426B2 (en) 2009-02-06 2015-06-11 Imago Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
BR112012021806A2 (pt) 2010-03-01 2015-09-08 Myrexis Inc compostos e seus usos terapêusticos.
US8404859B2 (en) 2011-03-16 2013-03-26 Hoffmann-La Roche Inc. Thiazole and thiophene compounds
EP2694509B1 (en) 2011-04-05 2016-05-18 Pfizer Limited Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases
EP2721029B1 (en) 2011-06-16 2018-07-18 Merck Sharp & Dohme Corp. Imidazopyridin-2-one derivatives
FR2998892B1 (fr) 2012-12-04 2015-01-02 Pf Medicament Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
US20160031907A1 (en) 2013-03-15 2016-02-04 Epizyme, Inc. Substituted Benzene Compounds
CA2939639C (en) 2014-02-24 2023-01-24 Takeda Gmbh Uti fusion proteins
CN107074788B (zh) 2014-10-31 2019-09-20 厦门大学 取代杂环衍生物、其制备方法和用途
US10202376B2 (en) 2014-12-24 2019-02-12 Takeda Pharmaceutical Company Limited Heterocyclic compound
TWI636041B (zh) 2015-08-12 2018-09-21 美國禮來大藥廠 Cgrp受體拮抗劑
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
WO2017033946A1 (ja) 2015-08-25 2017-03-02 武田薬品工業株式会社 複素環化合物
PL3439477T3 (pl) 2016-04-08 2020-11-16 Syngenta Participations Ag Mikrobiocydowe pochodne oksadiazolowe
EP3636281B1 (en) 2017-05-09 2023-11-01 Zhejiang University Method for treating depression, and pharmaceutical composition
US11230541B2 (en) 2017-07-28 2022-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3774800B1 (en) 2018-03-28 2024-11-13 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP6806735B2 (ja) 2018-05-30 2021-01-06 矢崎総業株式会社 車両用回路体および車両用回路体の製造方法
AU2019362061B2 (en) 2018-10-18 2024-09-26 Essa Pharma Inc Androgen receptor modulators and methods for their use
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
WO2020198710A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2020196828A1 (ja) 2019-03-28 2020-10-01 武田薬品工業株式会社 含窒素複素環化合物
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) * 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途

Similar Documents

Publication Publication Date Title
JP7846132B2 (ja) Nav1.8阻害薬としてのアリール 3-オキソピペラジンカルボキサミド類及びヘテロアリール 3-オキソピペラジンカルボキサミド類
JP7555327B2 (ja) Nlrp3インフラマソーム阻害剤
CN105073747B (zh) 杂环化合物及其应用
JP6832846B2 (ja) ヘテロ環化合物およびその用途
TW570917B (en) Trisubstituted 1,3,5-triazine derivatives
JP2026048891A (ja) Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類
JP2015512942A5 (cg-RX-API-DMAC10.html)
RU2472509C2 (ru) Способ лечения артрита
JP2014516360A5 (cg-RX-API-DMAC10.html)
JP2012503018A5 (cg-RX-API-DMAC10.html)
EA033686B1 (ru) Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа
JP2011509309A5 (cg-RX-API-DMAC10.html)
CN105308036A (zh) 用于激酶调节的化合物和方法及其适应症
JP2010513519A5 (cg-RX-API-DMAC10.html)
RU2012131416A (ru) Ингибиторы фосфатидилинозитол-3-киназы на основе изоиндолинона
HRP20131182T1 (hr) Novi derivati 6-triazolopiridazinsulfanilbenzotiazola i -benzimidazola, postupak njihovog dobivanja i primjena kao medikamenata i farmaceutskih pripravaka, te nova upotreba kao inhibitora met
JP2013510884A5 (cg-RX-API-DMAC10.html)
JP2022510925A5 (cg-RX-API-DMAC10.html)
JP2020533352A5 (cg-RX-API-DMAC10.html)
JP2010539166A5 (cg-RX-API-DMAC10.html)
HUE032075T2 (en) 3-(2-aryl-cycloalkenylmethyl)-oxazolidin-2-one derivatives as cholesterol ester transfer protein (cetp) inhibitors
JP2023512664A5 (cg-RX-API-DMAC10.html)
JP2011509301A5 (cg-RX-API-DMAC10.html)
JP2013542267A5 (cg-RX-API-DMAC10.html)
BR112020005279B1 (pt) Compostos de 4-[[(7-aminopirazolo[1,5-a]pirimidin-5- il)amino]metil] piperidin-3-ol como inibidores cdk, seus usos, composição farmacêutica e seu método de preparação, métodos in vitro para inibir a função de cdk em uma célula, e para inibir a proliferação celular, inibir a progressão do ciclo celular, promover apoptose ou uma combinação de um ou mais desses, e kit